Zymeworks stock gains 4.85 percent after 2026 outlook update

Published on 10/05/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks stock trades at USD 26.37 on Nasdaq on October 5, 2026, up 4.85 percent. Its revised 2026 revenue outlook is USD 278 million to USD 292 million after the Theravance deal.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks (ISIN US98985Y1082) was trading at USD 26.37 on Nasdaq on October 5, 2026, up 4.85 percent in the session. The biotechnology company recently completed its Theravance Biopharma acquisition and raised its 2026 financial outlook, giving the stock a sharper commercial cash-flow narrative.

Guidance resets the revenue base

In its September 28, 2026 release, Zymeworks set 2026 total revenue guidance at USD 278 million to USD 292 million and adjusted EBITDA guidance at USD 114 million to USD 128 million. The guidance follows the addition of YUPELRI, a commercial product acquired through Theravance, and excludes the impact of future transactions.

The transaction also changes the companys financing profile. Zymeworks said it accessed USD 600 million of non-dilutive financing during 2026, including a USD 350 million non-recourse note tied to YUPELRI cash flows.

YUPELRI adds measurable cash flow

The acquired asset supplied a concrete operating base before the deal closed. YUPELRI generated USD 133.1 million in total sales during the first half of 2026, resulting in USD 38.4 million of collaboration revenue to Theravance, according to Zymeworks. Hospital sales grew 25 percent year over year in the second quarter of 2026, a comparison that links the acquisition to an established commercial channel.

The counterweight is the legacy quarterly base. For the quarter ended June 30, 2026, revenue was USD 4.59 million and GAAP net loss was USD 45.02 million, compared with USD 48.73 million of revenue and USD 2.32 million of net profit a year earlier, Markets Insider reported on September 29, 2026.

Analysts see room above USD 26.37

StockAnalysis lists a Strong Buy consensus from 14 analysts, with an average price target of USD 41.07, a low of USD 32 and a high of USD 60. The average target lies 55.7 percent above the Nasdaq price of USD 26.37, although the targets and the live quote carry different dates.

Recent individual views also remain constructive. Markets Insider reported on September 29, 2026, that Jefferies maintained a Buy rating with a USD 50 price target and Citi maintained Buy with a USD 39 target.

Stock trades near its yearly midpoint

ZYME was trading at USD 26.37 on Nasdaq at 3:03 p.m. ET on October 5, 2026, with a session range of USD 25.28 to USD 26.52. Its 52-week range is USD 16.00 to USD 31.34, while market capitalization stood at USD 1.9 billion and volume at 376,173 shares.